Joana Woods

Joana Woods

Auto-generated profile, based on publicly available information

Joana Woods

Wits Ezintsha, Faculty of Health Sciences University of the Witwatersrand Johannesburg South Africa

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2020 in Southern African Journal of HIV Medicine
Verified
Journal Article
Open access
PDF file
JNJeremy Nel
Jeremy Nel
SDSipho Dlamini
Sipho Dlamini
GMGraeme Meintjes
Graeme Meintjes
RBRosie Burton
Rosie Burton
JBJohn M. Black
John M. Black
JWJoana F. Woods
Joana F. Woods
The Southern African Journal of HIV Medicine is focused on HIV/AIDS treatment, prevention and related topics relevant to clinical and public health practice. The purpose of the journal is to disseminate original research results and support high-level learning related to HIV Medicine. It publishes original research articles, editorials, case reports/case series, reviews of state-of-the-art clinical practice and correspondence.

1 August 2019 in Southern African Journal of HIV Medicine
Verified
Journal Article
Open access
JWJoana Woods
Joana Woods
MMMichelle Moorhouse
Michelle Moorhouse
LKLucia Knight
Lucia Knight
As South Africa's (SA) HIV programme increases in size, HIV/TB cases occur that are often beyond the clinical scope of primary healthcare clinicians. In SA's Eastern Cape (EC) province, health facilities are geographically widespread, with a discrepancy in specialist availability outside of academic institutions. The aim of this study is to describe WhatsApp and its use as an alternative learning tool to improve clinicians' access to specialised management of complicated HIV/TB cases. To analyse clinicians' use of the WhatsApp chat group as a learning tool; to assess clinicians' confidence in managing complicated HIV and TB patients after participating in the WhatsApp case discussion group; to describe the perceived usefulness of the chat group as a learning tool; to understand clinicians' knowledge and use of informed consent when sharing patient case details on a public platform such as WhatsApp. An observational, cross-sectional study was conducted among a group of clinicians from the EC that formed part of a WhatsApp HIV/TB clinical discussion group. Data were collected using a structured anonymous Internet questionnaire and analysed with Epi Info, using descriptive and analytic statistics. The analysis found the majority of participants had gained new clinical confidence from group participation. This was associated with the increased group engagement in group follow-up (odds ratio [OR] 48.13 [95% confidence interval [CI] 4.99-464.49]); in posting questions (OR 3.81 [95% CI 1.02-18.48]); in reports of 'new' clinical insights (OR 23.75 [95% CI 3.95-142.88]); in referencing old case material (OR 21.42 [95% CI 4.39-104.84]) and in the use of peer guidance to manage cases (OR 48.13 [95% CI 4.99-464.49]). However, there was a discrepancy in participants' knowledge and actual use of informed consent when posting patient details on social media. Our study findings support the use of WhatsApp in a medical setting as an effective means of communication, long distance learning and support between peers and specialists.

17 September 2024 in HIV Medicine
Verified
Journal Article
Open access
JWJoana Woods
Joana Woods
SSSimiso Sokhela
Simiso Sokhela
GAGodspower Akpomiemie
Godspower Akpomiemie
BBBronwyn Bosch
Bronwyn Bosch
KMKarlien Möller
Karlien Möller
WVWillem D. F. Venter
Willem D. F. Venter
Objectives: Treatment‐related weight gain and metabolic complications with antiretroviral integrase‐based regimens, especially among Black women, suggest the need for alternative options.Methods: We conducted a 48‐week, open‐label, single‐arm, single‐centre, phase IIIb switch study to evaluate the tolerability, safety and efficacy of switching from stable efavirenz‐ or dolutegravir‐based antiretroviral therapy to doravirine/lamivudine/tenofovir disoproxil fumarate in Black women.Results: The 101 participants enrolled (median age 35 years; interquartile range 31–40) were on efavirenz (n = 46; mean duration on therapy 1.7 years) or dolutegravir‐based (n = 55; mean duration 1.5 years) antiretrovirals at screening. Retention at 48 weeks was 92/101 participants, and viral suppression was >90% throughout the study, with a single case of doravirine resistance (106 M, V108I and H221Y mutations). The mean weight percentage change at week 48 was 4.7% (95% confidence interval [CI] 3.0–6.5; p < 0.001), and the adjusted mean change was 2.7 kg (95% CI 1.50–3.98; p < 0.001); for efavirenz, the percentage change was 5.0% (95% CI 2.9–7.1; p < 0.001), and the adjusted weight gain was 3.5 kg (95% CI 1.93–5.13); for dolutegravir, the percentage change was 4.5% (95% CI 1.8–7.3; p < 0.001), and the adjusted weight gain was 2.1 kg (95% CI 0.26–3.90). Statistically significant decreases in lipid panel percent mean to week 48 included: total cholesterol −8.4% (95% CI −11.3 to −5.5; p < 0.001), triglycerides −10.4% (95% CI −16.4 to −4.4; p < 0.001) and high‐density lipoprotein −14.8% (95% CI −18.5 to −11.2%; p < 0.001), with minor differences when disaggregating the mean percent change in lipids between previous efavirenz/dolutegravir regimens. Adverse events due to doravirine were few and mild.Conclusions: Our findings suggest that a switch to doravirine from efavirenz or dolutegravir is safe and effective in Black women, with significant improvement in lipid profiles, but does not arrest progressive weight gain.